Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inbrija for early morning OFF symptoms in Parkinson's Disease
NCT02807675Phase 1Completed
- Sponsor
- Acorda Therapeutics
- Start
- Jun 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of levodopa inhalation powder in Parkinson's disease (PD) (2 arms), sponsored by Acorda Therapeutics. Primary endpoint: Number of patients with Adverse Events (AEs) including Serious AEs up to 9 days. Started Jun 2016; status: completed.
02
Drugs
levodopa inhalation powder
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02807675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02807675.